Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.

Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) mainly expresses type-2 endotype, featuring eosinophils as a main player in the inflammatory process. Prolonged eosinophilia in the tissues of ...

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 consecutive robot-assisted, minimally invasive esophagectomies (RAMIE) performed from 2020–2024, as reported in ...

Patients with eosinophilic oesophagitis (EoE ... Younger age (< 30 years), longer treatment duration, and low treatment adherence were factors associated with off-label STC treatment failure.

"Treatment for mitochondrial diseases within reach." ScienceDaily. www.sciencedaily.com / releases / 2025 / 04 / 250409114701.htm (accessed April 22, 2025). Explore More ...

Prince Harry has claimed he was “singled out for inferior treatment” after he was stripped of his taxpayer-funded security protection in the UK. The Duke of Sussex, 40, arrived at London’s ...

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched ...

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched ...

Sun Pharmaceutical Industries introduced Fexuclue, a new medication for treating Erosive Esophagitis, in India. This PCAB drug aims to address the unmet needs in treatment. Rights were acquired from ...